Mi az ára Energenesis Biomedical CO.,LTD. (6657)

Energenesis Biomedical CO.,LTD. (6657) ára $0.97305026

Mi a Energenesis Biomedical CO.,LTD. (6657 piaci tőkésítése)

Energenesis Biomedical CO.,LTD. piaci tőkésítése (6657) $85.54M

Energenesis Biomedical CO.,LTD. (6657) P/B mutató

Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.

Év	P/B arány	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

P/B arány

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	P/B arány	P/B arány különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

P/B arány

P/B arány különbség

Ország